Rifaximin to Prevent Recurrent HCV-Related Fibrosis After Liver Transplant

Inclusion Criteria: * Subject must provide written informed consent before any study assessment is performed * Age ≥ 18 years * Willing and able to sign informed consent * Chronic HCV infection with viremia * Listed for liver transplantation * Demonstrate ability to take oral medications prior to randomization (post LT) Exclusion Criteria: * Age \< 18 years old * Unwilling/able to sign informed consent * Cleared HCV infection (and therefore not at risk for recurrent HCV) * Human immunodeficiency virus (HIV) co-infection * Hepatitis B (HBV) co-infection * Participation in another interventional clinical trial * Females of childbearing (reproductive) potential must have a negative serum pregnancy test at Screening and agree to use an acceptable method of contraception throughout their participation in the study * Subjects with history of hypersensitivity to rifaximin, rifampin, rifamycin antimicrobial agents, or any of the components of rifaximin * Subjects with history of tuberculosis infection or has received treatment for tuberculosis infection. If subject has previous positive test for tuberculosis antigen then they must have current negative chest x-ray to be eligible * Subject has diarrhea and positive Clostridium difficile (C. difficile) toxin via stool examination during Screening period. NOTE: Stool examination for C. difficile toxin will be performed on subjects who have diarrhea during the screening period. Results of stool tests should be confirmed as negative prior to randomization